Dermapharm Holding (DMP) Fair Value & Analysis
Healthcare · DE · Market cap €2.4B
Fair value as of: Jun 24, 2026
From 26 valuation models · updated 6 days ago
Fair value updated Jun 24, 2026 — revised from €45.96 to €50.48 (+9.8%) since Jun 23, 2026. Share price −3.3% over the past month.
Price vs Fair Value (12 months)
12‑month range €31.64 – €51.14 · fair‑value band €23.36 – €73.50 · the €46.55 price screens below the €50.48 fair value. As of Jun 24, 2026.
✦ Find undervalued quality stocks — 35,000+ analysed Find stocks →Analysis
Dermapharm Holding (DMP) currently trades at €46.55, while our model-based Fair Value estimate is €50.48 — implying the stock looks roughly 8.4% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, Dermapharm Holding generated revenue of €1.2B at a net margin of 12.2%. Revenue grew 1.3% year over year. It earns a return on equity of 20.8%. Net debt stands at €849M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany, Italy, France, Austria, Switzerland, Spain, Portugal, the Netherlands, Croatia, Poland, Ukraine, the United States, and China. The company operates through three segments: Branded Pharmaceuticals; Other Healthcare Products; and Parallel Import Business. It offers branded generics, OTC products, non-prescription healthcare products, and herbal extracts and parallel-imported originator pharmaceuticals. The company also provides vitamins, minerals, food supplements, as well as products for dermatology, allergology, pain and inflammation treatment, cardiovascular support, gynecology, and urology. In addition, it offers cosmetics and medical devices. Further, the company imports originator pharmaceuticals under the axicorp brand. It sells its products under the Dekristol, Keltican, Tromcardin, Ketozolin, bite away, and Herpotherm brands. The company was fou…
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Dermapharm Holding reported revenue of €1.2B in FY2025 versus €943M in FY2021, a compound +5.4%/yr. Reported net income was €132M in FY2025, compounding −10.8%/yr from FY2021.
Open the full interactive analysis →
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥47.08 | ¥26.59 | -44% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,786 | ₹991.46 | -44% |
| Zoetis Inc Z1TS34 | R$24.45 | R$6.33 | -74% |
| Hansoh Pharmaceutical Group 3692 | HK$29.30 | HK$23.90 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,639 | ₹1,281 | -81% |
| Swedish Orphan Biovitrum AB SOBI | kr 446.60 | kr 234.19 | -48% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Dermapharm Holding (DMP) undervalued?
What is the fair value of DMP?
What is the quality score of DMP?
What is the revenue of Dermapharm Holding (DMP)?
What is the net profit margin of DMP?
Does Dermapharm Holding pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.